Lead IGFBPL1 Fusion Protein Program
Retinal disorders, primarily Glaucoma (including normotensive glaucoma)
PreclinicalActive
Key Facts
Indication
Retinal disorders, primarily Glaucoma (including normotensive glaucoma)
Phase
Preclinical
Status
Active
Company
About FireCyte Therapeutics
FireCyte Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is engineering first-in-class fusion protein therapeutics designed to simultaneously engage SORT1 and DCC receptors to modulate neuroinflammation and provide direct neuroprotection. Its lead program targets retinal disorders like glaucoma, aiming to address a critical unmet need where current standard of care fails to halt disease progression, with a long-term vision to expand into other neurodegenerative conditions.
View full company profile